A splicing variant in XPA results in delayed onset of clinical features of xeroderma pigmentosum
Clinical Summary
View sourceWhat was studied
Two unrelated Cypriot XP-A patients homozygous for c.389G>A (p.R130K) were described, with clinical phenotypes and fibroblast-based assays of nucleotide excision repair (TC-NER, GG-NER) and XPA protein levels.
Key findings
Both patients’ fibroblasts showed a severe TC-NER defect and reduced GG-NER, with very low XPA protein levels despite a conservative amino acid change; clinically, the 69-year-old developed progressive neurologic degeneration in his 40s, while the 32-year-old has no neurologic abnormalities to date.
Study limitations
Only two cases from a single ancestry are reported, limiting generalizability; the abstract provides no quantitative repair metrics and appears truncated, leaving mechanistic details incomplete.
Clinical implications
XP-A due to c.389G>A (p.R130K) can present with mild cutaneous disease yet later neurologic decline; functional testing can reveal marked NER defects even when the variant appears conservative, and adult patients may warrant ongoing neurologic surveillance.
Related Questions
Explore related topics and deepen your understanding